We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





PCR System Moves Ultra-Fast Testing From Lab to Patients at Point of Need

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Sal6830 Point of Care PCR System (Photo courtesy of MicroGEM International)
Image: Sal6830 Point of Care PCR System (Photo courtesy of MicroGEM International)

A next generation person-portable diagnostic device aims to move complex molecular biology testing out of highly skilled laboratories to non-laboratory settings where they can be used quickly at the point of need.

MicroGEM International’s (Charlottesville, VA, USA) Sal6830 Point of Care PCR System is a pathogen detection and gene expression system relevant in both the infectious disease and precision medicine fields, and produces lab-quality results in 27 minutes. Its innovative cartridge design allows new targets to be added or replaced quickly, significantly reducing both assay and product development time. The platform's small size is easily incorporated at testing sites such as mobile testing labs, ambulatory surgical centers, emergency departments, and CLIA-waived testing sites at the workplace.

The Sal6830 SARS-CoV-2 Saliva Test is the first validated test for the Sal6830 Point of Care PCR System. It is also the first FDA emergency use authorized saliva test for SARS-CoV-2 using PCR directly at the point of care where people can wait for fast results after providing a sample. The test is designed to capture and enrich viruses and cells, including bacteria and epithelial cells, from saliva and then detect extracted RNA from the SARS-CoV-2 virus if present in the saliva specimen. The approach automates and integrates saliva sample collection, nucleic acid extraction, reverse transcription, real-time ultra-fast PCR amplification, and detection of the target sequences in a simple design.  The technology employs simplified automation with essentially no moving parts and provides easy-to-read visual cues indicating whether SARS-CoV-2 is detected (+) or not detected (-)

Clinically tested during both the Delta and Omicron waves of the pandemic, the Sal6830 SARS-CoV-2 Saliva Test has proven to be robust through the viral mutations that have occurred. The Sal6830 SARS-CoV-2 Saliva Test is easy to operate. Its simple workflow and easy saliva collection reduce workload for healthcare workers and limit their exposure to the sample. Requiring only a small amount of saliva, it eliminates the discomfort of swab testing, making it more comfortable for routine testing. The company's plans include seeking authorization to expand the test menu and ruggedize the system to address austere field conditions presented in military and disaster medicine. Plans are also underway to adapt the system for the fast-growing precision medicine healthcare market with quantitative gene expression panels used as biomarkers.

"The introduction of the MicroGEM Sal6830 Point of Care PCR System marks a historic step in our mission to democratize molecular diagnostics by moving ultra-fast, high-performance testing out of laboratories and closer to people at the point of need, thus allowing decisions to be made in real time," said MicroGEM CEO Jeff Chapman.

Related Links:
MicroGEM International 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.